Leyden Labs is pioneering a novel approach to combat respiratory viruses by developing nasal sprays that deliver antibodies directly to the nasal mucosa. This method aims to halt initial infections at the entry point of these viruses, thereby preventing further transmission. The company focuses on harnessing mucosal immunity, which has shown promise in providing more effective protection compared to traditional systemic administration. By optimizing the delivery of intranasally-administered antibodies, Leyden Labs seeks to create products that offer immediate antiviral protection and are accessible for self-administration.

In addition to their focus on mucosal immunity, Leyden Labs emphasizes the importance of broad protection against evolving respiratory viruses. Their research targets specific viral epitopes to ensure that their therapies remain effective against multiple strains and potential new variants. The company draws inspiration from the CR9114 antibody, known for its broad neutralizing capabilities against influenza, and aims to develop products that can provide lasting protection in the face of viral evolution. Leyden Labs is currently advancing its lead program, PanFlu™, through clinical trials, with the goal of delivering innovative solutions for future pandemic preparedness.

Netherlands

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families.

The Leyden Labs’ energetic team of world-renowned biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Leyden Labs

Company Details